Dr Reddys Laboratories Ltd Hits Intraday High with 3.56% Surge on 3 Feb 2026

Intraday Trading Highlights

The pharmaceutical giant opened the day with a significant gap up of 7.33%, immediately setting a positive tone for the trading session. The stock maintained its upward trajectory, touching a peak price of Rs 1269.05 before settling with a day change of 3.56%. This performance marked a reversal after two consecutive days of decline, signalling renewed buying interest within the session.

Dr Reddys Laboratories Ltd outpaced the Pharmaceuticals & Biotechnology sector, which itself gained 2.66% on the day. The stock’s 3.94% gain over the day also exceeded the Sensex’s 2.72% rise, underscoring its relative strength amid broader market movements.

Technical Positioning and Moving Averages

From a technical standpoint, the stock closed above its 5-day and 20-day moving averages, indicating short-term bullish momentum. However, it remained below its 50-day, 100-day, and 200-day moving averages, suggesting that medium to long-term resistance levels are yet to be breached. This mixed technical picture reflects a stock in recovery mode but still facing some headwinds from longer-term trend lines.

The Sensex, meanwhile, experienced a volatile day. After opening 3,656.74 points higher, it lost momentum and fell by 1,415.02 points, closing at 83,908.18, down 2.74%. Despite this, the index remains close to its 52-week high of 86,159.02, just 2.68% away. The Sensex is trading below its 50-day moving average, though the 50DMA remains above the 200DMA, indicating a cautiously positive medium-term trend.

Performance Metrics and Market Capitalisation

Dr Reddys Laboratories Ltd currently holds a Mojo Score of 43.0 with a Mojo Grade of Sell, reflecting a downgrade from Hold on 14 Jan 2026. The company’s market cap grade stands at 1, indicating a relatively modest market capitalisation within its peer group. Despite the recent downgrade, the stock’s intraday strength today highlights a notable shift in trading dynamics.

Examining the stock’s performance over various time frames provides further context. Over the past week, the stock declined by 0.90%, underperforming the Sensex’s 2.48% gain. Over one month, it fell 2.11%, closely tracking the Sensex’s 2.18% decline. However, over three months, Dr Reddys Laboratories Ltd gained 2.71%, outperforming the Sensex’s marginal 0.10% loss. Year-to-date, the stock is down 3.32%, compared to the Sensex’s 1.56% decline.

Longer-term returns show a mixed picture: a 41.00% gain over three years versus the Sensex’s 37.88%, but a more modest 32.12% rise over five years compared to the Sensex’s 66.93%. Over a decade, the stock has appreciated by 104.29%, lagging the Sensex’s 246.33% growth.

Sector and Market Context

The Pharmaceuticals & Biotechnology sector, to which Dr Reddys Laboratories Ltd belongs, recorded a 2.66% gain on the day, supported by broad-based buying interest. This sector outperformance relative to the Sensex’s 2.74% rise indicates selective strength in healthcare-related stocks despite the broader market’s volatility.

Within this environment, Dr Reddys Laboratories Ltd’s 3.56% gain and intraday high of Rs 1269.05 stand out as a strong performance signal. The stock’s ability to open with a gap up of 7.33% and sustain gains above short-term moving averages suggests active trading interest and a positive shift in market sentiment during the session.

Summary of Trading Action

Dr Reddys Laboratories Ltd’s strong intraday performance on 3 Feb 2026 was characterised by a decisive gap up opening and sustained gains throughout the session. The stock’s 3.56% rise outpaced both its sector and the broader Sensex index, signalling a notable shift after a brief period of decline. Technical indicators show the stock trading above its short-term moving averages, though longer-term resistance remains in place.

The broader market environment was mixed, with the Sensex retreating after an initial surge but remaining close to its 52-week high. The Pharmaceuticals & Biotechnology sector’s positive performance provided a supportive backdrop for Dr Reddys Laboratories Ltd’s gains.

Overall, the stock’s intraday high of Rs 1269.05 and gap up opening reflect a session of strong buying interest and active trading, marking a significant move within the current market context.

Unlock special upgrade rates for a limited period. Start Saving Now →